J Chem Inf Model - Quantitative structure-activity relationship models of clinical pharmacokinetics: clearance and volume of distribution.

Tópicos

{ compound(1573) activ(1297) structur(1058) }
{ model(3404) distribut(989) bayesian(671) }
{ model(2656) set(1616) predict(1553) }
{ medic(1828) order(1363) alert(1069) }
{ process(1125) use(805) approach(778) }
{ perform(1367) use(1326) method(1137) }
{ error(1145) method(1030) estim(1020) }
{ concept(1167) ontolog(924) domain(897) }
{ model(2341) predict(2261) use(1141) }
{ imag(2675) segment(2577) method(1081) }
{ data(3963) clinic(1234) research(1004) }
{ state(1844) use(1261) util(961) }
{ gene(2352) biolog(1181) express(1162) }
{ structur(1116) can(940) graph(676) }
{ system(1976) rule(880) can(841) }
{ sequenc(1873) structur(1644) protein(1328) }
{ featur(3375) classif(2383) classifi(1994) }
{ design(1359) user(1324) use(1319) }
{ control(1307) perform(991) simul(935) }
{ method(984) reconstruct(947) comput(926) }
{ perform(999) metric(946) measur(919) }
{ blood(1257) pressur(1144) flow(957) }
{ data(2317) use(1299) case(1017) }
{ signal(2180) analysi(812) frequenc(800) }
{ cost(1906) reduc(1198) effect(832) }
{ sampl(1606) size(1419) use(1276) }
{ data(1737) use(1416) pattern(1282) }
{ measur(2081) correl(1212) valu(896) }
{ studi(2440) review(1878) systemat(933) }
{ framework(1458) process(801) describ(734) }
{ data(1714) softwar(1251) tool(1186) }
{ search(2224) databas(1162) retriev(909) }
{ import(1318) role(1303) understand(862) }
{ studi(1119) effect(1106) posit(819) }
{ model(3480) simul(1196) paramet(876) }
{ ehr(2073) health(1662) electron(1139) }
{ research(1218) medic(880) student(794) }
{ first(2504) two(1366) second(1323) }
{ time(1939) patient(1703) rate(768) }
{ can(981) present(881) function(850) }
{ analysi(2126) use(1163) compon(1037) }
{ high(1669) rate(1365) level(1280) }
{ drug(1928) target(777) effect(648) }
{ method(2212) result(1239) propos(1039) }
{ can(774) often(719) complex(702) }
{ imag(1947) propos(1133) code(1026) }
{ inform(2794) health(2639) internet(1427) }
{ imag(1057) registr(996) error(939) }
{ bind(1733) structur(1185) ligand(1036) }
{ method(1219) similar(1157) match(930) }
{ imag(2830) propos(1344) filter(1198) }
{ network(2748) neural(1063) input(814) }
{ patient(2315) diseas(1263) diabet(1191) }
{ take(945) account(800) differ(722) }
{ motion(1329) object(1292) video(1091) }
{ assess(1506) score(1403) qualiti(1306) }
{ treatment(1704) effect(941) patient(846) }
{ surgeri(1148) surgic(1085) robot(1054) }
{ problem(2511) optim(1539) algorithm(950) }
{ chang(1828) time(1643) increas(1301) }
{ learn(2355) train(1041) set(1003) }
{ clinic(1479) use(1117) guidelin(835) }
{ algorithm(1844) comput(1787) effici(935) }
{ extract(1171) text(1153) clinic(932) }
{ method(1557) propos(1049) approach(1037) }
{ model(2220) cell(1177) simul(1124) }
{ care(1570) inform(1187) nurs(1089) }
{ general(901) number(790) one(736) }
{ featur(1941) imag(1645) propos(1176) }
{ case(1353) use(1143) diagnosi(1136) }
{ howev(809) still(633) remain(590) }
{ studi(1410) differ(1259) use(1210) }
{ risk(3053) factor(974) diseas(938) }
{ research(1085) discuss(1038) issu(1018) }
{ system(1050) medic(1026) inform(1018) }
{ visual(1396) interact(850) tool(830) }
{ spatial(1525) area(1432) region(1030) }
{ record(1888) medic(1808) patient(1693) }
{ health(3367) inform(1360) care(1135) }
{ monitor(1329) mobil(1314) devic(1160) }
{ patient(2837) hospit(1953) medic(668) }
{ age(1611) year(1155) adult(843) }
{ group(2977) signific(1463) compar(1072) }
{ data(3008) multipl(1320) sourc(1022) }
{ intervent(3218) particip(2042) group(1664) }
{ activ(1138) subject(705) human(624) }
{ patient(1821) servic(1111) care(1106) }
{ use(2086) technolog(871) perceiv(783) }
{ health(1844) social(1437) communiti(874) }
{ cancer(2502) breast(956) screen(824) }
{ use(976) code(926) identifi(902) }
{ use(1733) differ(960) four(931) }
{ result(1111) use(1088) new(759) }
{ implement(1333) system(1263) develop(1122) }
{ survey(1388) particip(1329) question(1065) }
{ estim(2440) model(1874) function(577) }
{ decis(3086) make(1611) patient(1517) }
{ activ(1452) weight(1219) physic(1104) }
{ method(1969) cluster(1462) data(1082) }
{ detect(2391) sensit(1101) algorithm(908) }

Resumo

Reliable prediction of two fundamental human pharmacokinetic (PK) parameters, systemic clearance (CL) and apparent volume of distribution (Vd), determine the size and frequency of drug dosing and are at the heart of drug discovery and development. Traditionally, estimated CL and Vd are derived from preclinical in vitro and in vivo absorption, distribution, metabolism, and excretion (ADME) measurements. In this paper, we report quantitative structure-activity relationship (QSAR) models for prediction of systemic CL and steady-state Vd (Vdss) from intravenous (iv) dosing in humans. These QSAR models avoid uncertainty associated with preclinical-to-clinical extrapolation and require two-dimensional structure drawing as the sole input. The clean, uniform training sets for these models were derived from the compilation published by Obach et al. (Drug Metab. Disp. 2008, 36, 1385-1405). Models for CL and Vdss were developed using both a support vector regression (SVR) method and a multiple linear regression (MLR) method. The SVR models employ a minimum of 2048-bit fingerprints developed in-house as structure quantifiers. The MLR models, on the other hand, are based on information-rich electro-topological states of two-atom fragments as descriptors and afford reverse QSAR (RQSAR) analysis to help model-guided, in silico modulation of structures for desired CL and Vdss. The capability of the models to predict iv CL and Vdss with acceptable accuracy was established by randomly splitting data into training and test sets. On average, for both CL and Vdss, 75% of test compounds were predicted within 2.5-fold of the value observed and 90% of test compounds were within 5.0-fold of the value observed. The performance of the final models developed from 525 compounds for CL and 569 compounds for Vdss was evaluated on an external set of 56 compounds. The predictions were either better or comparable to those predicted by other in silico models reported in the literature. To demonstrate the practical application of the RQSAR approach, the structure of vildagliptin, a high-CL and a high-Vdss compound, is modified based on the atomic contributions to its predicted CL and Vdss to propose compounds with lower CL and lower Vdss.

Resumo Limpo

reliabl predict two fundament human pharmacokinet pk paramet system clearanc cl appar volum distribut vd determin size frequenc drug dose heart drug discoveri develop tradit estim cl vd deriv preclin vitro vivo absorpt distribut metabol excret adm measur paper report quantit structureact relationship qsar model predict system cl steadyst vd vdss intraven iv dose human qsar model avoid uncertainti associ preclinicaltoclin extrapol requir twodimension structur draw sole input clean uniform train set model deriv compil publish obach et al drug metab disp model cl vdss develop use support vector regress svr method multipl linear regress mlr method svr model employ minimum bit fingerprint develop inhous structur quantifi mlr model hand base informationrich electrotopolog state twoatom fragment descriptor afford revers qsar rqsar analysi help modelguid silico modul structur desir cl vdss capabl model predict iv cl vdss accept accuraci establish random split data train test set averag cl vdss test compound predict within fold valu observ test compound within fold valu observ perform final model develop compound cl compound vdss evalu extern set compound predict either better compar predict silico model report literatur demonstr practic applic rqsar approach structur vildagliptin highcl highvdss compound modifi base atom contribut predict cl vdss propos compound lower cl lower vdss

Resumos Similares

J Chem Inf Model - Automated selection of compounds with physicochemical properties to maximize bioavailability and druglikeness. ( 0,791465702289538 )
J Chem Inf Model - QSAR classification model for antibacterial compounds and its use in virtual screening. ( 0,780690959518221 )
J Chem Inf Model - A new protocol for predicting novel GSK-3? ATP competitive inhibitors. ( 0,765393097194354 )
J Am Med Inform Assoc - Drug repurposing: mining protozoan proteomes for targets of known bioactive compounds. ( 0,75849949856179 )
J Chem Inf Model - In silico enzymatic synthesis of a 400,000 compound biochemical database for nontargeted metabolomics. ( 0,746502650467151 )
J Chem Inf Model - Rationalizing the role of SAR tolerance for ligand-based virtual screening. ( 0,746450995368647 )
J Chem Inf Model - Hsp90 inhibitors, part 2: combining ligand-based and structure-based approaches for virtual screening application. ( 0,743171567022516 )
J Chem Inf Model - Construction and use of fragment-augmented molecular Hasse diagrams. ( 0,743152654847705 )
J Chem Inf Model - A multivariate chemical similarity approach to search for drugs of potential environmental concern. ( 0,741046137110351 )
J Chem Inf Model - Large-scale assessment of activity landscape feature probabilities of bioactive compounds. ( 0,740851689426933 )
J Chem Inf Model - Combining horizontal and vertical substructure relationships in scaffold hierarchies for activity prediction. ( 0,74052177734789 )
J Chem Inf Model - Fighting high molecular weight in bioactive molecules with sub-pharmacophore-based virtual screening. ( 0,739728001279357 )
J Chem Inf Model - Structure based model for the prediction of phospholipidosis induction potential of small molecules. ( 0,738617587592042 )
J Chem Inf Model - Visual characterization and diversity quantification of chemical libraries: 1. creation of delimited reference chemical subspaces. ( 0,738264548582178 )
J Chem Inf Model - Identification of novel malarial cysteine protease inhibitors using structure-based virtual screening of a focused cysteine protease inhibitor library. ( 0,73708200009185 )
J Chem Inf Model - Design of multitarget activity landscapes that capture hierarchical activity cliff distributions. ( 0,734635375869396 )
J Chem Inf Model - De novo design of drug-like molecules by a fragment-based molecular evolutionary approach. ( 0,732767445597217 )
J Chem Inf Model - Structural similarity based kriging for quantitative structure activity and property relationship modeling. ( 0,732653962143932 )
J Chem Inf Model - Enumeration of 166 billion organic small molecules in the chemical universe database GDB-17. ( 0,731693963857814 )
J Chem Inf Model - TIN-a combinatorial compound collection of synthetically feasible multicomponent synthesis products. ( 0,731159982847463 )
J Chem Inf Model - Predictions of BuChE inhibitors using support vector machine and naive Bayesian classification techniques in drug discovery. ( 0,730961315693382 )
J Chem Inf Model - Identification of a new class of FtsZ inhibitors by structure-based design and in vitro screening. ( 0,730567780406415 )
J Chem Inf Model - Polypharmacology directed compound data mining: identification of promiscuous chemotypes with different activity profiles and comparison to approved drugs. ( 0,730281015787803 )
J Chem Inf Model - Capturing structure-activity relationships from chemogenomic spaces. ( 0,72799688106946 )
J Chem Inf Model - Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity. ( 0,727838886366598 )
J Chem Inf Model - Discovery of novel antimalarial compounds enabled by QSAR-based virtual screening. ( 0,726378627715261 )
J Chem Inf Model - Modeling drug-induced anorexia by molecular topology. ( 0,724005101255098 )
J Chem Inf Model - Profile-QSAR and Surrogate AutoShim protein-family modeling of proteases. ( 0,723083937639231 )
Curr Comput Aided Drug Des - Development of Chemical Compound Libraries for In Silico Drug Screening. ( 0,722510687866487 )
J Chem Inf Model - Locating sweet spots for screening hits and evaluating pan-assay interference filters from the performance analysis of two lead-like libraries. ( 0,722368165572779 )
J Chem Inf Model - Discovery and design of tricyclic scaffolds as protein kinase CK2 (CK2) inhibitors through a combination of shape-based virtual screening and structure-based molecular modification. ( 0,722243414055593 )
J Chem Inf Model - Selection of in silico drug screening results for G-protein-coupled receptors by using universal active probes. ( 0,721748913436188 )
J Chem Inf Model - Compound set enrichment: a novel approach to analysis of primary HTS data. ( 0,720413736997381 )
J Chem Inf Model - G-protein coupled receptors virtual screening using genetic algorithm focused chemical space. ( 0,718540836853475 )
J Chem Inf Model - How diverse are diversity assessment methods? A comparative analysis and benchmarking of molecular descriptor space. ( 0,716710960840789 )
J Chem Inf Model - Binary classification of a large collection of environmental chemicals from estrogen receptor assays by quantitative structure-activity relationship and machine learning methods. ( 0,715053786997717 )
J Chem Inf Model - Characterizing the diversity and biological relevance of the MLPCN assay manifold and screening set. ( 0,713686497758801 )
J Chem Inf Model - BioSM: metabolomics tool for identifying endogenous mammalian biochemical structures in chemical structure space. ( 0,713554681042218 )
J Chem Inf Model - Similarity boosted quantitative structure-activity relationship--a systematic study of enhancing structural descriptors by molecular similarity. ( 0,710999219338897 )
J Chem Inf Model - Effective screening strategy using ensembled pharmacophore models combined with cascade docking: application to p53-MDM2 interaction inhibitors. ( 0,71070687431761 )
J Chem Inf Model - Identification of novel liver X receptor activators by structure-based modeling. ( 0,710131954509287 )
J Integr Bioinform - Database supported candidate search for metabolite identification. ( 0,709668185816385 )
J Chem Inf Model - Prediction of synthetic accessibility based on commercially available compound databases. ( 0,708985273953005 )
J Chem Inf Model - Identification of multitarget activity ridges in high-dimensional bioactivity spaces. ( 0,708600273585963 )
J Chem Inf Model - Statistical analysis and compound selection of combinatorial libraries for soluble epoxide hydrolase. ( 0,708204795454588 )
J Chem Inf Model - Natural product-like virtual libraries: recursive atom-based enumeration. ( 0,708167528538988 )
J Chem Inf Model - Synthesis, bioassay, and molecular field topology analysis of diverse vasodilatory heterocycles. ( 0,708046650540138 )
J Chem Inf Model - Novel mycosin protease MycP1 inhibitors identified by virtual screening and 4D fingerprints. ( 0,707462647828878 )
J Chem Inf Model - Conditional probabilistic analysis for prediction of the activity landscape and relative compound activities. ( 0,705248908641031 )
J Chem Inf Model - Ligand- and structure-based virtual screening for clathrodin-derived human voltage-gated sodium channel modulators. ( 0,705152881039549 )
J Chem Inf Model - Compound optimization through data set-dependent chemical transformations. ( 0,704872080594841 )
J Chem Inf Model - Chemical data visualization and analysis with incremental generative topographic mapping: big data challenge. ( 0,703483367364107 )
J Chem Inf Model - Systematic assessment of compound series with SAR transfer potential. ( 0,703115200212554 )
J Chem Inf Model - Automated recycling of chemistry for virtual screening and library design. ( 0,70221640134886 )
J Chem Inf Model - Target-independent prediction of drug synergies using only drug lipophilicity. ( 0,701766023305482 )
J Chem Inf Model - Increasing the coverage of medicinal chemistry-relevant space in commercial fragments screening. ( 0,70167968963267 )
J Chem Inf Model - Experimentally validated HERG pharmacophore models as cardiotoxicity prediction tools. ( 0,701225077219102 )
J Chem Inf Model - Discovery of novel histamine H4 and serotonin transporter ligands using the topological feature tree descriptor. ( 0,700644397098643 )
J Chem Inf Model - Application of quantitative structure-activity relationship models of 5-HT1A receptor binding to virtual screening identifies novel and potent 5-HT1A ligands. ( 0,69926344134 )
J Chem Inf Model - Discovery of a7-nicotinic receptor ligands by virtual screening of the chemical universe database GDB-13. ( 0,699024251065532 )
J Chem Inf Model - Identification of a novel inhibitor of dengue virus protease through use of a virtual screening drug discovery Web portal. ( 0,698895636810737 )
J Chem Inf Model - From activity cliffs to activity ridges: informative data structures for SAR analysis. ( 0,698462884716796 )
J Chem Inf Model - Exploring uncharted territories: predicting activity cliffs in structure-activity landscapes. ( 0,697171102893512 )
J Chem Inf Model - ColBioS-FlavRC: a collection of bioselective flavonoids and related compounds filtered from high-throughput screening outcomes. ( 0,696438281423799 )
J Chem Inf Model - Multitarget structure-activity relationships characterized by activity-difference maps and consensus similarity measure. ( 0,696123786689709 )
J Chem Inf Model - Identification of 1,2,5-oxadiazoles as a new class of SENP2 inhibitors using structure based virtual screening. ( 0,696092038752845 )
J Chem Inf Model - Knowledge-based libraries for predicting the geometric preferences of druglike molecules. ( 0,695422473733204 )
Brief. Bioinformatics - State-of-the-art technology in modern computer-aided drug design. ( 0,695371001179418 )
J Chem Inf Model - Optimization of molecular representativeness. ( 0,695326977775328 )
J Chem Inf Model - Prediction of individual compounds forming activity cliffs using emerging chemical patterns. ( 0,695158810356631 )
J Chem Inf Model - Searching for recursively defined generic chemical patterns in nonenumerated fragment spaces. ( 0,695007019310293 )
J Chem Inf Model - Library enhancement through the wisdom of crowds. ( 0,694202003204013 )
J Chem Inf Model - Integrating medicinal chemistry, organic/combinatorial chemistry, and computational chemistry for the discovery of selective estrogen receptor modulators with Forecaster, a novel platform for drug discovery. ( 0,693133913805818 )
J Chem Inf Model - Identifying compound-target associations by combining bioactivity profile similarity search and public databases mining. ( 0,692381118307315 )
J Chem Inf Model - Discovery of new selective human aldose reductase inhibitors through virtual screening multiple binding pocket conformations. ( 0,691686098982604 )
J Chem Inf Model - PyDPI: freely available python package for chemoinformatics, bioinformatics, and chemogenomics studies. ( 0,691313773436611 )
J Chem Inf Model - A searchable map of PubChem. ( 0,690278147731262 )
J Chem Inf Model - Navigating high-dimensional activity landscapes: design and application of the ligand-target differentiation map. ( 0,689949516462229 )
J Chem Inf Model - Application of computer-aided drug repurposing in the search of new cruzipain inhibitors: discovery of amiodarone and bromocriptine inhibitory effects. ( 0,689782991244062 )
J Chem Inf Model - Mining the ChEMBL database: an efficient chemoinformatics workflow for assembling an ion channel-focused screening library. ( 0,688709592204223 )
J Chem Inf Model - A comparison of different QSAR approaches to modeling CYP450 1A2 inhibition. ( 0,687816746238992 )
J Chem Inf Model - How experimental errors influence drug metabolism and pharmacokinetic QSAR/QSPR models. ( 0,687688243704912 )
J Chem Inf Model - Visualization and virtual screening of the chemical universe database GDB-17. ( 0,687490718330443 )
J Chem Inf Model - SMIfp (SMILES fingerprint) chemical space for virtual screening and visualization of large databases of organic molecules. ( 0,687389641741534 )
J Chem Inf Model - AlzPlatform: an Alzheimer's disease domain-specific chemogenomics knowledgebase for polypharmacology and target identification research. ( 0,687076344944674 )
J Chem Inf Model - Scanning structure-activity relationships with structure-activity similarity and related maps: from consensus activity cliffs to selectivity switches. ( 0,686936485633807 )
J Chem Inf Model - Atom pair 2D-fingerprints perceive 3D-molecular shape and pharmacophores for very fast virtual screening of ZINC and GDB-17. ( 0,686835481124944 )
J Chem Inf Model - Best of both worlds: on the complementarity of ligand-based and structure-based virtual screening. ( 0,686520153416747 )
J Chem Inf Model - Improving classical substructure-based virtual screening to handle extrapolation challenges. ( 0,686077078383098 )
J Chem Inf Model - Frequency of occurrence and potency range distribution of activity cliffs in bioactive compounds. ( 0,683008771092977 )
J Chem Inf Model - Multiple e-pharmacophore modeling, 3D-QSAR, and high-throughput virtual screening of hepatitis C virus NS5B polymerase inhibitors. ( 0,682980905282955 )
J Chem Inf Model - Scaffold diversity of exemplified medicinal chemistry space. ( 0,682598142717839 )
J Chem Inf Model - Identification of novel S-adenosyl-L-homocysteine hydrolase inhibitors through homology-model-based virtual screening, synthesis, and biological evaluation. ( 0,681724820396102 )
J Chem Inf Model - Freely available conformer generation methods: how good are they? ( 0,681337889411736 )
J Chem Inf Model - Scaffold-focused virtual screening: prospective application to the discovery of TTK inhibitors. ( 0,680936462127329 )
J Chem Inf Model - Identification of novel serotonin transporter compounds by virtual screening. ( 0,680748994924003 )
J Chem Inf Model - Searching for substructures in fragment spaces. ( 0,680720196598175 )
J Chem Inf Model - SABRE: ligand/structure-based virtual screening approach using consensus molecular-shape pattern recognition. ( 0,678428050992362 )
J Chem Inf Model - Design of a three-dimensional multitarget activity landscape. ( 0,677792203818374 )
J Chem Inf Model - Discovery of chemical compound groups with common structures by a network analysis approach (affinity prediction method). ( 0,676853102735124 )